Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Diel

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 18, 2008
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records reviewIngo J Diel, Rudolf Weide, Hubert Köppler, et al.
Pain|September 15, 2004
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerJean-Jacques Body, Ingo J Diel, Richard Bell, et al.
Journal of Clinical Medicine|April 14, 2026
Delayed Care in Self-Presenting Stroke Patients: Real-World Data on Process Delays-Comparing Process Times Between Emergency Medical Services and Self-PresentationChristian Claudi, Patrick Schramm, Martin Juenemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesJ-J Body, I J Diel, M R Lichinitser, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2004
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancerI J Diel, J-J Body, M R Lichinitser, et al.
American Journal of Obstetrics and Gynecology|April 4, 2007
Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapyFlorian Schuetz, Ingo J Diel, Marit Pueschel, et al.
British Journal of Cancer|February 13, 2001
Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myelomaH W Woitge, M Pecherstorfer, E Horn, et al.
The British Journal of Ophthalmology|May 2, 2019
Individuals with migraine have a different dry eye symptom profile than individuals without migraineMonika Farhangi, Ryan J Diel, Dawn C Buse, et al.
Nature Medicine|April 3, 2001
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrowM Feuerer, P Beckhove, L Bai, et al.
Critical Care (London, England)|May 9, 2026
Etiology- and age-specific timing of death by neurologic criteria evaluation and declaration in clinical practiceKristian Barlinn, Daniela Schoene, Konrad Pleul, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 18, 2008
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records reviewIngo J Diel, Rudolf Weide, Hubert Köppler, et al.
Pain|September 15, 2004
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerJean-Jacques Body, Ingo J Diel, Richard Bell, et al.
Journal of Clinical Medicine|April 14, 2026
Delayed Care in Self-Presenting Stroke Patients: Real-World Data on Process Delays-Comparing Process Times Between Emergency Medical Services and Self-PresentationChristian Claudi, Patrick Schramm, Martin Juenemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesJ-J Body, I J Diel, M R Lichinitser, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2004
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancerI J Diel, J-J Body, M R Lichinitser, et al.
American Journal of Obstetrics and Gynecology|April 4, 2007
Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapyFlorian Schuetz, Ingo J Diel, Marit Pueschel, et al.
British Journal of Cancer|February 13, 2001
Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myelomaH W Woitge, M Pecherstorfer, E Horn, et al.
The British Journal of Ophthalmology|May 2, 2019
Individuals with migraine have a different dry eye symptom profile than individuals without migraineMonika Farhangi, Ryan J Diel, Dawn C Buse, et al.
Nature Medicine|April 3, 2001
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrowM Feuerer, P Beckhove, L Bai, et al.
Critical Care (London, England)|May 9, 2026
Etiology- and age-specific timing of death by neurologic criteria evaluation and declaration in clinical practiceKristian Barlinn, Daniela Schoene, Konrad Pleul, et al.
Pageof 9